GSK hails five-year ViiV Healthcare data on HIV treatment Cabenuva
(Alliance News) - GSK PLC on Wednesday noted five-year data for ViiV Healthcare's HIV treatment Cabenuva, which the lead study author found "highly encouraging".
The London-based pharmaceutical company noted a study that showed 77% of participants remained in care and on long-acting HIV treatment Cabenuva with a median treatment duration of 18 months.
Furthermore, 94% of individuals who switched to Cabenuva had a last viral load of less than 50 copies per millilitre of blood plasma, while 81% maintained continuous viral suppression with only 1% experiencing confirmed virologic failure.
Ricky Hsu, lead study author, said: "By evaluating nearly 7,000 individuals in routine clinical care, this analysis gathered over the five-year OPERA study adds to and strengthens the clinical and real-world evidence base for long-acting cabotegravir and rilpivirine.
"The data offer vital, highly encouraging insights around treatment persistence with the long-acting therapy, showing that overall discontinuations were low and not commonly attributed to a lack of therapeutic efficacy or injection site pain. These are important insights for healthcare providers as they consider the full breadth of treatment options available to their patients."
Jean van Wyk, chief medical officer at ViiV Healthcare, said: "Long-term, real-world evidence is critical to help us better understand the impact of HIV treatment outside of the clinical trial setting.
"In this analysis gathered over five years from the OPERA cohort, cabotegravir and rilpivirine demonstrated durable and consistent viral suppression within a large and diverse patient population, with high persistence in routine care."
The findings will be shown at IDWeek 2026 in Washington DC between Wednesday and Saturday.
GSK shares were 0.3% higher at 1,874.00 pence each on Wednesday afternoon in London.
By Tom Budszus, Alliance News slot editor
Comments and questions to newsroom@alliancenews.com
Copyright 2026 Alliance News Ltd. All Rights Reserved.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
6 ETFs To Diversify Away From AI
Are TIPS ETFs the Best Way to Fight Inflation?
What’s Ahead for Stocks This Quarter—and Where to Invest
United States